News

Back

Micro Medical Solutions receives CE Mark for key technologies

Wilmington, MA March 14, 2016—Micro Medical Solutions announces it has received European CE Mark approval for two of its key innovations. “This approval paves the way for the final stage of development for our proprietary Micro Vascular Integrated Platform,” said Gregory Sullivan, CEO of Micro Medical Solutions. The Micro Vascular Integrated Platform (mVIP) will include the MicroBalloon and MicroGuide, designed for treatment of critical limb ischemia (CLI) lesions that are Below the Knee (BTK). 510K approvals for the MicroGuide and MicroBalloon were competed recently, and 510K approval and CE Mark for the components of the platform are expected to follow in 2017.

CONTACT: Peg Thornton, Director of Corporate and Market Development, Micro Medical Solutions 732-616-9123

About CLI

Peripheral artery disease (PAD) and critical limb ischemia (CLI) affected 215 million people worldwide in 2015, predicted to be 230 million by 2020.1 CLI currently afflicts 2.8 to 3.5 million of those with PAD and is projected to rise to 4.5 to 5.6 million.2 Rates of amputations in the general population with PAD are declining, but amputations in CLI continue to escalate. It has been estimated that 25% of CLI patients will undergo major amputation. Prognosis with respect to limb preservation in CLI patients is poor, particularly in no-option CLI patients, where six-month major amputation rates have been reported to be as high as 50%.3 If something doesn’t change, the number of amputations due to CLI could exceed one million by 2030.

References: 1. Global Peripheral Artery Disease Market: Trends & Opportunities (2015-2020), February 2016 (Page 19). Daedal Research Group. 2. Critical Limb Ischemia. Volume 1 United States Epidemiology, 2010. Accessed at http://thesagegroup.us/pages/rep[orts/cliepiusreprot.php., October 14, 2016. 3. Teraa M, Conte MS, Moll FL, Verhaar MC. Contemporary Reviews: Critical Limb Ischemia: Current Trends and Future Directions. J Am Heart Assoc 2016; 5: e002938.

Back To Top